Skip to main content
Premium Trial:

Request an Annual Quote

Discovery Partners International Completes Acquisition of Xenometrix

NEW YORK, May 9 – Discovery Partners International has completed its acquisition of  gene profiling technology company Xenometrix, the company said Wednesday.

Xenometrix of Boulder, Colo., is the latest addition to Discovery Partners’ drug discovery technology offerings. In February, Discovery Partners signed the initial agreement to acquire Xenometrix for $1.7 million. 

On May 4, Discovery Partners shareholders approved the deal. Under the terms of the agreement, Discovery Partners has agreed to purchase all of Xenometrix’s common stock at a share price of 59 cents per share—a 46 premium over its closing price of 41 cents per share the day before the deal closed. Xenometrix will now be operated as a wholly owned subsidiary of Discovery Partners. 

This acquisition provides Discovery Partners with unfettered access to Xenometrix’s patented gene profiling technology, which Xenometrix has licensed to Affymetrix, Aurora Biosciences, Corning, Gene Logic, GeneTrace, Genometrix, Genzyme, Motorola, Packard, Pfizer, Phase-1, Rosetta Inpharmatics, and GlaxoSmithKline.  

Xenometrix also has proprietary genotoxicity technology that enables high throughput screening for genotoxicity, and its bioinformatics team has been assembling a database of gene profiles for public domain pharmaceuticals.  

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.